BioAtla downgraded by Credit Suisse with a new price target

5/5/22 6:12:47 AM ET

Biotechnology: Biological Products (No Diagnostic Substances)

Health Care

Credit Suisse downgraded BioAtla from Outperform to Neutral and set a new price target of $5.00 from $35.00 previously

Save time and jump to the most important pieces.

Recent Analyst Ratings for
$BCAB

Date	Price Target	Rating	Analyst
11/13/2024		Buy → Neutral	H.C. Wainwright
9/15/2022	$17.00	Mkt Outperform	JMP Securities
5/5/2022	$35.00 → $5.00	Outperform → Neutral	Credit Suisse
3/21/2022	$25.00	Buy	H.C. Wainwright
10/15/2021	$68.00	Buy	BTIG Research
6/28/2021	$75.00	Buy	ROTH Capital